MARKET WIREYahoo! Finance Canada • 17h ago
Aurora Cannabis Inc. (ACB) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
Why ACB Stock slipped -0.49% Today — RQD Quant Desk Flash
$4.06 -0.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.05
Aurora Cannabis Inc. (ACB) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $251.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ACB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ACB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Aurora Cannabis Inc. (NASDAQ: ACB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $4.06 (-0.49% 1D, market cap $251.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ACB ranks #219 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ACB compare to USNA and CGC in the Health Care sector?
▼
Within the Health Care sector (Medicinal Chemicals and Botanical Products), ACB carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, USNA (USANA Health Sciences Inc.) holds a D grade (50/100 RQD, P/E 24.6x, ROIC 7.9%, cap $264.4M) and CGC (Canopy Growth Corporation) posts a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $276.0M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ACB?
▼
For Aurora Cannabis Inc. (ACB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #219 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.05 (-0.28%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.2% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-1.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACB)Realized 20D OHLCV Swing Band: ±7.4%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY ACB SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (22% of score)
SEC XBRL Trailing 12 Months: 0.2% FCF Margin ($7.0M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$4.29-7.5% Next Q
62
Q2 (-2Q)Grade C$3.97+4.5% Next Q
59
Q3 (-1Q)Grade C$4.15-2.2% Next Q
57
CurrentGrade D+$4.06-0.7% Hist 90D α
54
Trajectory: C+ (62) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ACB Turnaround Squeeze
While ACB currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.05) and Max Pain ($4.26) forces dealer call-delta covering toward $6.68.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ACB Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ACB Stock slipped -0.49% Today — RQD Quant Desk Flash
Aurora Cannabis Inc. (ACB) slipped -0.49% to $4.06, trading at 39% of its 52-week range ($2.56 – $6.36). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 39% of its 52-week range ($2.56 – $6.36) with RSI-14 at 50.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.4% around $4.06 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $7.0M annual free cash flow.
Live ACB Headlines & Catalysts
CATALYSTThe Motley Fool • 20h ago
Aurora Cannabis Stock Has Soared 25% Since Curaleaf First Made an Offer to Buy Its Business. Here's Why I Think It Can Go Even HigherThe Motley Fool report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 23h ago
Curaleaf enhances offer to acquire Aurora Cannabis (CURLF:OTCMKTS)Seeking Alpha report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
CATALYST24/7 Wall St. • 1d ago
Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease24/7 Wall St. report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStocktwits • 1d ago
Aurora Cannabis Highlights Inaccuracies In Curaleaf’s Takeover Bid Announcement— CEO Claims Business Is Reaching Pivotal Inflection PointStocktwits report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance UK • 1d ago
Aurora Cannabis Inc. (ACB) stock price, news, quote and historyYahoo Finance UK report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Curaleaf raises Aurora Cannabis offer by 25%Yahoo Finance report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 3d ago
Top 3 Canadian Healthcare Stocks To Watch In October 2026China and Switzerland just agreed to scrap tariffs on most traded goods, including Swiss medical devices, which puts a global spotlight on healthcare products and technology. That kind of cross border opening can sharpen
CATALYSTYahoo • 3d ago
Forget Rescheduling: Green Thumb's Cash Flow Is the Real Reason to Own ItIf Green Thumb's high cash flow persists, regulatory progress could fuel a massive rally for this profitable marijuana stock.
MARKET WIREYahoo • 4d ago
Aurora Cannabis to Host Second Quarter 2027 Investor Conference CallEDMONTON, Alberta, October 29, 2026--Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it will host an investor co
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACB)
- ✓Walkthrough of ACB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ACB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.71%🛡️ HOLDING TREND SUPPORT
2026-11-03O $4.08H $4.08L $4.06C $4.06VOL 807.2K
RES: $4.87SUP: $3.95SMA50: $4.05SMA200: $3.54
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ACB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ACB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ACB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ACB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACB)
Health Care Rank #219 of 1016
⚔️ USNA vs ACB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ACB vs. USNA, CGC, SNDL, GLAS)
Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Aurora Cannabis Inc. (ACB) ranks #219 by composite RQD confidence (54/100, grade D+) and #540 by equity capitalization ($251.5M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. ACB currently leads its immediate peer cohort in composite quantitative strength at 54/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACB
ACTIVE
Aurora Cannabis Inc. | D+ | 54/100 | — | — | — | -0.49% | $251.5M | Benchmark Subject |
| USNA USANA Health Sciences Inc. | D | 50/100 | 24.6x | 78.3% | 7.9% | -0.21% | $264.4M | /usna-vs-acb → |
| CGC Canopy Growth Corporation | D- | 41/100 | — | — | — | -3.33% | $276.0M | /cgc-vs-acb → |
| SNDL SNDL Inc. | D | 47/100 | — | — | — | -4.61% | $301.7M | /sndl-vs-acb → |
| GLAS Glass House Brands Inc. Subordinate Voting Shares | E | 18/100 | — | 42.3% | -9.2% | -4.39% | $191.8M | /glas-vs-acb → |
2. ACB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTAurora Cannabis Inc. (ACB) operates in Medicinal Chemicals and Botanical Products (Health Care) with an equity capitalization of $251.5M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. ACB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ACB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Aurora Cannabis Inc. (NASDAQ: ACB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $4.06 (-0.49% 1D, market cap $251.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ACB ranks #219 in composite RQD confidence.
How does ACB compare to USNA and CGC in the Health Care sector?
Within the Health Care sector (Medicinal Chemicals and Botanical Products), ACB carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, USNA (USANA Health Sciences Inc.) holds a D grade (50/100 RQD, P/E 24.6x, ROIC 7.9%, cap $264.4M) and CGC (Canopy Growth Corporation) posts a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $276.0M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ACB?
For Aurora Cannabis Inc. (ACB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #219 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ACB trading relative to its 50-day, 200-day, and 52-week technical levels?
ACB last traded at $4.06 (-0.49% on volume of 807,217 shares), positioning the stock +0.25% above its 50-day simple moving average ($4.05) and +14.69% above its 200-day simple moving average ($3.54). Across its 52-week range of $2.56 to $6.36, ACB sits at the 39.5% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±7.4% ($3.76 to $4.36).
ACB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ACB stock moving today?
Why ACB Stock slipped -0.49% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 54/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ACB — Aurora Cannabis Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:17:06Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ACB scores 54 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:
- Fundamental Cash Engine (12/20): Reported as ROIC 0% and FCF yield 0%. Per the market data section, the company shows 0% gross, operating, and net margins. For a prospective investor, this pillar indicates no measurable cash generation in the source data to anchor valuation.
- Whale 13F Flow (9/20): Institutional accumulation and options positioning. The source data does not provide 13F holder detail, so the score is not traceable to specific holders.
- Insider Conviction (9/20): SEC Form 4 and Congressional PTR cluster flow. The holders section contains no insider transactions, so the score cannot be traced to specific trades.
- Macro Regime Fit (11/20): Beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level sensitivity per the market data section; the sector sensitivity detail is not itemized in the source data.
- Forensic Balance Sheet (13/20): Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5. This is the strongest pillar and suggests a balance sheet that is not in acute distress on these measures, though no financial statements are provided to verify components.
Investment implications: the composite score points to weak fundamentals on the cash-generation pillar, with the balance-sheet pillar offering the main offset. Upside drivers would need to come from catalysts rather than current earnings or cash flow. Valuation tradeoffs are difficult to assess because P/E, EV/EBITDA, and EPS are not available in source data. This is educational analysis, not personalized financial advice.
Business
Aurora Cannabis Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Medicinal Chemicals and Botanical Products industry, per the profile section. The profile describes the company as operating in this industry with a market capitalization of $0.3B. The source data does not itemize product lines, customers, or revenue model.
Recent Catalysts & News Wire Analysis
Per the recent news section, six items relate to ACB. The headlines reference a takeover bid by Curaleaf, with coverage describing an offer to buy the business (Motley Fool), an enhanced offer (Seeking Alpha), and a company response disputing inaccuracies in the bid announcement and citing a "pivotal inflection point" (Stocktwits). A 24/7 Wall St. item notes ACB easing alongside other cannabis names on a day Tilray fell. Several items are tagged as market wire, catalyst, or green/yellow signals, but the source data does not define these labels. Risk watch items include the unresolved status of the takeover bid and the absence of financial detail to evaluate the company's response to it. The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are therefore not available in source data. The only sector-level context is the Health Care classification and the Medicinal Chemicals and Botanical Products industry. Investors should watch whether the pending takeover activity described in the news section alters the company's sector positioning, but the source data does not quantify any such ripple.
Open Questions
- What are the reported revenue, operating income, net income, and free cash flow figures for recent periods, given that the financials section is empty?
- What are the terms and current status of the Curaleaf takeover bid, and how do they compare with the current price of 4.08?
- What are the specific 13F holders, Form 4 insider trades, and Congressional PTR filings that support the whale and insider pillar scores?
- Why are P/E, EV/EBITDA, and EPS unavailable, and what would earnings-based valuation look like?
- What is the basis for the 0% ROIC and FCF yield figures, and are they representative of current operations?
ACB Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Aurora Cannabis Inc. (ACB) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 17h ago
Aurora Cannabis Inc. (ACB) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST The Motley Fool • 20h ago
Aurora Cannabis Stock Has Soared 25% Since Curaleaf First Made an Offer to Buy Its Business. Here's Why I Think It Can Go Even Higher The Motley Fool report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 23h ago
Curaleaf enhances offer to acquire Aurora Cannabis (CURLF:OTCMKTS) Seeking Alpha report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST 24/7 Wall St. • 1d ago
Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease 24/7 Wall St. report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stocktwits • 1d ago
Aurora Cannabis Highlights Inaccuracies In Curaleaf’s Takeover Bid Announcement— CEO Claims Business Is Reaching Pivotal Inflection Point Stocktwits report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 1d ago
Aurora Cannabis Inc. (ACB) stock price, news, quote and history Yahoo Finance UK report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Curaleaf raises Aurora Cannabis offer by 25% Yahoo Finance report covering Aurora Cannabis Inc. (ACB) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo • 3d ago
Top 3 Canadian Healthcare Stocks To Watch In October 2026 China and Switzerland just agreed to scrap tariffs on most traded goods, including Swiss medical devices, which puts a global spotlight on healthcare products and technology. That kind of cross border opening can sharpen
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ACB Bull vs. Bear Conversation Board — What's Your Call at $4.06?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACB 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $4.41 (+8.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ACB (D+ • RQD 54/100) a Buy at $4.08?
Welcome to the ACB (Aurora Cannabis Inc.) Roar Pit. Current RQD Composite is 54/100 (Roarable Sell — Weak Fundamentals / Trim) in Medicinal Chemicals and Botanical Products. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $3.43 (-15.9%)
Spot @ $4.08 Pump the brakes on ACB — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ACB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Aurora Cannabis Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $5.06 (+24.0%)
Spot @ $4.08 ACB cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ACB, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $4.08 (52-wk range $2.56 - $6.36), any beat on forward guidance forces shorts and underweight funds to chase.